Andrea Alvarez Eslava, MD
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1154504157
Payments from drug & device makers
Across 68 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$941
- Abbott$384
- Lilly USA, LLC$164
- Dexcom, Inc.$158
- Cequr Corporation$133
- Soleno Therapeutics, Inc.$130
- plus $712 from 14 others
What the payments were for
- Food & beverage$2,52696%
- Education$974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $941 |
| Abbott | 10 | $384 |
| Lilly USA, LLC | 9 | $164 |
| Dexcom, Inc. | 2 | $158 |
| Cequr Corporation | 2 | $133 |
| Soleno Therapeutics, Inc. | 1 | $130 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Tandem Diabetes Care, Inc. | 1 | $97 |
| Mannkind Corporation | 5 | $86 |
| Insulet Corporation | 1 | $72 |
| Corcept Therapeutics | 2 | $65 |
| Ascensia Diabetes Care US Inc. | 3 | $65 |
| Tolmar, Inc. | 3 | $56 |
| Amgen | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Acerus Pharmaceuticals Corporation | 1 | $21 |
| Averitas Pharma Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$240
- VYKAT XR$130
- DISEASE STATE$125
- Wegovy$122
- CeQur Simplicity$116
- Ozempic$116
- FreeStyle Libre$101
- DEXCOM G6 TRANSMITTER$101
How this compares
$2,622 in reported general payments places this provider in the 40th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 31 | $284 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.